目的：研究胃癌组织中miR-29的表达情况及其与临床病理特征和预后的关系。方法：收集2005年至2010年中国人民解放军第324医院收治的进展期胃癌113例患者的手术标本，定量PCR检测胃癌组织及癌旁组织内miR-29的表达，并分析其与胃癌患者临床病理特征的关系。结果：胃癌组织内miR-29的表达显著低于对应的癌旁组织（2.62±1.17 vs 3.14±1.70，P=0.006），伴淋巴结转移的胃癌患者低表达miR-29百分率显著高于无淋巴结转移组（58.9% vs 32.5%，P=0.007），miR-29低表达胃癌患者中位生存率显著低于miR-29高表达者（33.0 vs 44.0个月，P=0.013）。结论：胃癌组织低表达miR-29，miR-29有可能成为胃癌的预后判断指标及治疗靶标。

Objective:To explore the expression of miR-29 in gastric cancer and its relationship with clinic pathological features and prognosis of gastric cancer. Methods: Totally 113 gastric cancer samples were obtained from patients who received operation during 2005 to 2010 in the No. 324 Hospital of PLA. The expression of miR-29 in gastric cancer and paracancerous tissues was detected by real-time PCR, and its relationship with clinic pathological features of gastric cancer was analyzed. Results: The expression of miR-29 in gastric cancer tissues was significantly lower than that in paracancerous tissues (2.62±1.17 vs 3.14±1.70, P=0.006). The rate of low miR-29 expression in patients with lymph node metastases was significantly higher than that without lymph node metastases (58.9% vs 32.5%, P=0.007). The median survival rate in low miR-29 expression cases was significantly lower than that in high miR-29 expression cases (33.0 vs 44.0 month, P=0.013). Conclusion: miR-29 is lowly expressed in gastric cancer tissues, and it might be used for prediction of prognosis and as for targeted treatment of gastric cancer.

重庆市自然科学基金资助项目（No. 2008BB5274，No. 2009BB5314，No. 2010BB5158）